68 related articles for article (PubMed ID: 15741747)
1. Plasma catecholamine levels after fluoxetine treatment in depressive patients.
Blardi P; de Lalla A; Auteri A; Iapichino S; Dell'Erba A; Castrogiovanni P
Neuropsychobiology; 2005; 51(2):72-6. PubMed ID: 15741747
[TBL] [Abstract][Full Text] [Related]
2. Fluoxetine once every third day in the treatment of major depressive disorder.
Tural U; Onder E
Eur Arch Psychiatry Clin Neurosci; 2003 Dec; 253(6):307-12. PubMed ID: 14714120
[TBL] [Abstract][Full Text] [Related]
3. Serotonin and fluoxetine levels in plasma and platelets after fluoxetine treatment in depressive patients.
Blardi P; De Lalla A; Leo A; Auteri A; Iapichino S; Di Muro A; Dell'Erba A; Castrogiovanni P
J Clin Psychopharmacol; 2002 Apr; 22(2):131-6. PubMed ID: 11910257
[TBL] [Abstract][Full Text] [Related]
4. Can serotonin and fluoxetine levels in plasma and platelets predict clinical response in depression?
Castrogiovanni P; Blardi P; De Lalla A; Dell'Erba A; Auteri A
Psychopharmacol Bull; 2003; 37(2):102-8. PubMed ID: 14566218
[TBL] [Abstract][Full Text] [Related]
5. Predictors of fluoxetine remission for hospitalized patients with major depressive disorder.
Lin CH; Lane HY; Chen CC; Juo SH; Yen CF
Psychiatry Clin Neurosci; 2011 Aug; 65(5):510-7. PubMed ID: 21851460
[TBL] [Abstract][Full Text] [Related]
6. Fluoxetine versus trimipramine in the treatment of depression in geriatric patients.
Wehmeier PM; Kluge M; Maras A; Riemann D; Berger M; Kohnen R; Dittmann RW; Gattaz WF
Pharmacopsychiatry; 2005 Jan; 38(1):13-6. PubMed ID: 15706460
[TBL] [Abstract][Full Text] [Related]
7. A randomized, double-blind, and placebo-controlled trial of quetiapine augmentation of fluoxetine in major depressive disorder.
Garakani A; Martinez JM; Marcus S; Weaver J; Rickels K; Fava M; Hirschowitz J
Int Clin Psychopharmacol; 2008 Sep; 23(5):269-75. PubMed ID: 18703936
[TBL] [Abstract][Full Text] [Related]
8. Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial.
Detke MJ; Wiltse CG; Mallinckrodt CH; McNamara RK; Demitrack MA; Bitter I
Eur Neuropsychopharmacol; 2004 Dec; 14(6):457-70. PubMed ID: 15589385
[TBL] [Abstract][Full Text] [Related]
9. Antidepressant response and well-being in pre-, peri- and postmenopausal women with major depressive disorder treated with fluoxetine.
Cassano P; Soares CN; Cusin C; Mascarini A; Cohen LS; Fava M
Psychother Psychosom; 2005; 74(6):362-5. PubMed ID: 16244512
[TBL] [Abstract][Full Text] [Related]
10. A double-blind, placebo-controlled comparison of venlafaxine and fluoxetine treatment in depressed outpatients.
Nemeroff CB; Thase ME;
J Psychiatr Res; 2007; 41(3-4):351-9. PubMed ID: 16165158
[TBL] [Abstract][Full Text] [Related]
11. Effect of mirtazapine treatment on serotonin transporter in blood peripheral lymphocytes of major depression patients.
Peña S; Baccichet E; Urbina M; Carreira I; Lima L
Int Immunopharmacol; 2005 Jun; 5(6):1069-76. PubMed ID: 15829422
[TBL] [Abstract][Full Text] [Related]
12. Early fluoxetine treatment of post-stroke depression--a three-month double-blind placebo-controlled study with an open-label long-term follow up.
Fruehwald S; Gatterbauer E; Rehak P; Baumhackl U
J Neurol; 2003 Mar; 250(3):347-51. PubMed ID: 12638027
[TBL] [Abstract][Full Text] [Related]
13. Serotonin transporter is differentially localized in subpopulations of lymphocytes of major depression patients. Effect of fluoxetine on proliferation.
Fazzino F; Montes C; Urbina M; Carreira I; Lima L
J Neuroimmunol; 2008 May; 196(1-2):173-80. PubMed ID: 18462811
[TBL] [Abstract][Full Text] [Related]
14. Preliminary randomized double-blind placebo-controlled trial of tryptophan combined with fluoxetine to treat major depressive disorder: antidepressant and hypnotic effects.
Levitan RD; Shen JH; Jindal R; Driver HS; Kennedy SH; Shapiro CM
J Psychiatry Neurosci; 2000 Sep; 25(4):337-46. PubMed ID: 11022398
[TBL] [Abstract][Full Text] [Related]
15. Psychic and somatic anxiety symptoms as predictors of response to fluoxetine in major depressive disorder.
Papakostas GI; McGrath P; Stewart J; Charles D; Chen Y; Mischoulon D; Dording C; Fava M
Psychiatry Res; 2008 Oct; 161(1):116-20. PubMed ID: 18755514
[TBL] [Abstract][Full Text] [Related]
16. Morning fluoxetine plus evening mianserin versus morning fluoxetine plus evening placebo in the acute treatment of major depression.
Dam J; Ryde L; Svejsø J; Lauge N; Lauritsen B; Bech P
Pharmacopsychiatry; 1998 Mar; 31(2):48-54. PubMed ID: 9562208
[TBL] [Abstract][Full Text] [Related]
17. Switching to reboxetine: an efficacy and safety study in patients with major depressive disorder unresponsive to fluoxetine.
Fava M; McGrath PJ; Sheu WP;
J Clin Psychopharmacol; 2003 Aug; 23(4):365-9. PubMed ID: 12920412
[TBL] [Abstract][Full Text] [Related]
18. Residual symptoms after remission of major depressive disorder with fluoxetine and risk of relapse.
Iovieno N; van Nieuwenhuizen A; Clain A; Baer L; Nierenberg AA
Depress Anxiety; 2011 Feb; 28(2):137-44. PubMed ID: 21284066
[TBL] [Abstract][Full Text] [Related]
19. Different effects of nifedipine and amlodipine on circulating catecholamine levels in essential hypertensive patients.
de Champlain J; Karas M; Nguyen P; Cartier P; Wistaff R; Toal CB; Nadeau R; Larochelle P
J Hypertens; 1998 Nov; 16(11):1357-69. PubMed ID: 9856375
[TBL] [Abstract][Full Text] [Related]
20. Difference in pre- and post-treatment plasma DHEA levels were significantly and positively correlated with difference in pre- and post-treatment Hamilton depression scores following successful therapy for major depression.
Hsiao CC
Psychoneuroendocrinology; 2006 Aug; 31(7):839-46. PubMed ID: 16716529
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
